Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Sarcoma Research
Published in: Clinical Sarcoma Research 1/2013

Open Access 01-12-2013 | Research

MicroRNA expression in Epstein-Barr virus-associated post-transplant smooth muscle tumours is related to leiomyomatous phenotype

Authors: Danny Jonigk, Nicole Izykowski, Lavinia Maegel, Eileen Schormann, Britta Maecker-Kolhoff, Florian Laenger, Hans Kreipe, Kais Hussein

Published in: Clinical Sarcoma Research | Issue 1/2013

Login to get access

Abstract

Epstein-Barr virus (EBV)-associated post-transplant smooth muscle tumours (PTSMT) are rare complications. In our previous molecular analysis, we have evaluated the expression of regulatory microRNA which are known to be EBV-related (miR-146a and miR-155) but found no deregulation in PTSMT. In this current analysis, we aimed to characterize the expression profiles of several hundred microRNA. Tissue samples from PTSMT and uterine leiomyomas were analysed by quantitative real-time PCR for the expression of 365 mature microRNA. PTSMT and leiomyomas share a highly similar microRNA profile, e.g. strong expression of miR-143/miR-145 cluster and low expression of miR-200c. Among EBV-related microRNA (miR-10b, miR-21, miR-29b, miR-34a, miR-127, miR-146a, miR-155, miR-200b, miR-203 and miR-429) only miR-10b and miR-203 were significantly deregulated. The expression pattern of microRNA in PTSMT is not associated with EBV infection but reflects the leiomyomatous differentiation of the tumour cells.
Appendix
Available only for authorised users
Literature
1.
Shroff R, Rees L: The post-transplant lymphoproliferative disorder - a literature review. Pediatr Nephrol. 2004, 19: 369-377. 10.1007/s00467-003-1392-xCrossRefPubMed
2.
Jonigk D, Laenger F, Maegel L: Molecular and clinicopathological analysis of Epstein-Barr virus-associated posttransplant smooth muscle tumors. Am J Transplant. 2012, 12: 1908-1917. 10.1111/j.1600-6143.2012.04011.xCrossRefPubMed
3.
Ong KW, Teo M, Lee V: Expression of EBV latent antigens, mammalian target of rapamycin, and tumor suppression genes in EBV-positive smooth muscle tumors: clinical and therapeutic implications. Clin Cancer Res. 2009, 15: 5350-5358. 10.1158/1078-0432.CCR-08-2979CrossRefPubMed
4.
Hussein K: Pathobiology of the microRNA system. Pathologe. 2012, 33: 70-78. 10.1007/s00292-011-1469-4CrossRefPubMed
5.
6.
Fitzgerald JB, Chennathukuzhi V, Koohestani F, Nowak RA, Christenson LK: Role of microRNA-21 and programmed cell death 4 in the pathogenesis of human uterine leiomyomas. Fertil Steril. 2012, 98: 726-734. e2, 10.1016/j.fertnstert.2012.05.040PubMedCentralCrossRefPubMed
7.
Chuang TD, Panda H, Luo X, Chegini N: miR-200c is aberrantly expressed in leiomyomas in an ethnic-dependent manner and targets ZEBs, VEGFA, TIMP2, and FBLN5. Endocr Relat Cancer. 2012, 19: 541-556. 10.1530/ERC-12-0007PubMedCentralCrossRefPubMed
8.
Georgieva B, Milev I, Minkov I, Dimitrova I, Bradford AP, Baev V: Characterization of the uterine leiomyoma microRNAome by deep sequencing. Genomics. 2012, 99: 275-281. 10.1016/j.ygeno.2012.03.003CrossRefPubMed
9.
Zavadil J, Ye H, Liu Z: Profiling and functional analyses of microRNAs and their target gene products in human uterine leiomyomas. PLoS One. 2010, 5: e12362- 10.1371/journal.pone.0012362PubMedCentralCrossRefPubMed
10.
Pan Q, Luo X, Chegini N: MicroRNA 21: response to hormonal therapies and regulatory function in leiomyoma, transformed leiomyoma and leiomyosarcoma cells. Mol Hum Reprod. 2010, 16: 215-227.PubMedCentralCrossRefPubMed
11.
Peng Y, Laser J, Shi G: Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma. Mol Cancer Res. 2008, 6: 663-673. 10.1158/1541-7786.MCR-07-0370CrossRefPubMed
12.
Nuovo GJ, Schmittgen TD: Benign metastasizing leiomyoma of the lung: clinicopathologic, immunohistochemical, and micro-RNA analyses. Diagn Mol Pathol. 2008, 17: 145-150. 10.1097/PDM.0b013e31815aca19PubMedCentralCrossRefPubMed
13.
Pan Q, Luo X, Chegini N: Differential expression of microRNAs in myometrium and leiomyomas and regulation by ovarian steroids. J Cell Mol Med. 2008, 12: 227-240.PubMedCentralCrossRefPubMed
14.
Marsh EE, Lin Z, Yin P, Milad M, Chakravarti D, Bulun SE: Differential expression of microRNA species in human uterine leiomyoma versus normal myometrium. Fertil Steril. 2008, 89: 1771-1776. 10.1016/j.fertnstert.2007.05.074PubMedCentralCrossRefPubMed
15.
Wang T, Zhang X, Obijuru L: A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas. Genes Chromosomes Cancer. 2007, 46: 336-347. 10.1002/gcc.20415CrossRefPubMed
16.
Danielson LS, Menendez S, Attolini CS: A differentiation-based microRNA signature identifies leiomyosarcoma as a mesenchymal stem cell-related malignancy. Am J Pathol. 2010, 177: 908-917. 10.2353/ajpath.2010.091150PubMedCentralCrossRefPubMed
17.
Shi G, Perle MA, Mittal K: Let-7 repression leads to HMGA2 overexpression in uterine leiomyosarcoma. J Cell Mol Med. 2009, 13: 3898-3905. 10.1111/j.1582-4934.2008.00541.xPubMedCentralCrossRefPubMed
18.
Hussein K, Theophile K, Büsche G: Aberrant microRNA expression pattern in myelodysplastic bone marrow cells. Leuk Res. 2010, 34: 1169-1174. 10.1016/j.leukres.2010.04.012CrossRefPubMed
19.
Jonigk D, Merk M, Hussein K: Obliterative airway remodeling: molecular evidence for shared pathways in transplanted and native lungs. Am J Pathol. 2011, 178: 599-608. 10.1016/j.ajpath.2010.10.032PubMedCentralCrossRefPubMed
20.
Onnis A, Navari M, Antonicelli G: Epstein-Barr nuclear antigen 1 induces expression of the cellular microRNA hsa-miR-127 and impairing B-cell differentiation in EBV-infected memory B cells. New insights into the pathogenesis of Burkitt lymphoma. Blood Cancer J. 2012, 2: e84- 10.1038/bcj.2012.29PubMedCentralCrossRefPubMed
21.
Rosato P, Anastasiadou E, Garg N: Differential regulation of miR-21 and miR-146a by Epstein-Barr virus-encoded EBNA2. Leukemia. 2012, 26: 2343-2352. 10.1038/leu.2012.108PubMedCentralCrossRefPubMed
22.
Forte E, Salinas RE, Chang C: The Epstein-Barr virus (EBV)-induced tumor suppressor microRNA MiR-34a is growth promoting in EBV-infected B cells. J Virol. 2012, 86: 6889-6898. 10.1128/JVI.07056-11PubMedCentralCrossRefPubMed
23.
Yu H, Lu J, Zuo L, Yan Q, Yu Z, Li X, Huang J, Zhao L, Tang H, Luo Z, Liao Q, Zeng Z, Zhang J, Li G: Epstein-Barr virus downregulates microRNA203 through the oncoprotein latent membrane protein 1: a contribution to increased tumor incidence in epithelial cells. J Virol. 2012, 86: 3088-3099. 10.1128/JVI.05901-11PubMedCentralCrossRefPubMed
24.
Du ZM, Hu LF, Wang HY, Yan LX, Zeng YX, Shao JY, Ernberg I: Upregulation of MiR-155 in nasopharyngeal carcinoma is partly driven by LMP1 and LMP2A and downregulates a negative prognostic marker JMJD1A. PLoS One. 2011, 6: e19137- 10.1371/journal.pone.0019137PubMedCentralCrossRefPubMed
25.
Linnstaedt SD, Gottwein E, Skalsky RL, Luftig MA, Cullen BR: Virally induced cellular microRNA miR-155 plays a key role in B-cell immortalization by Epstein-Barr virus. J Virol. 2010, 84: 11670-11678. 10.1128/JVI.01248-10PubMedCentralCrossRefPubMed
26.
Li G, Wu Z, Peng Y: MicroRNA-10b induced by Epstein-Barr virus-encoded latent membrane protein-1 promotes the metastasis of human nasopharyngeal carcinoma cells. Cancer Lett. 2010, 299: 29-36. 10.1016/j.canlet.2010.07.021CrossRefPubMed
27.
Ellis-Connell AL, Iempridee T, Xu I, Mertz JE: Cellular microRNAs200b and 429 regulate the Epstein-Barr virus switch between latency and lytic replication. J Virol. 2010, 84: 10329-10343. 10.1128/JVI.00923-10PubMedCentralCrossRefPubMed
28.
Lin Z, Wang X, Fewell C, Cameron J, Yin Q, Flemington EK: Differential expression of the miR-200 family microRNAs in epithelial and B cells and regulation of Epstein-Barr virus reactivation by the miR-200 family member miR-429. J Virol. 2010, 84: 7892-7897. 10.1128/JVI.00379-10PubMedCentralCrossRefPubMed
29.
Shinozaki A, Sakatani T, Ushiku T: Downregulation of microRNA-200 in EBV-associated gastric carcinoma. Cancer Res. 2010, 70: 4719-4727. 10.1158/0008-5472.CAN-09-4620CrossRefPubMed
30.
Yin Q, Wang X, Fewell C: MicroRNAmiR-155 inhibits bone morphogenetic protein (BMP) signaling and BMP-mediated Epstein-Barr virus reactivation. J Virol. 2010, 84: 6318-6327. 10.1128/JVI.00635-10PubMedCentralCrossRefPubMed
31.
Anastasiadou E, Boccellato F, Vincenti S: Epstein-Barr virus encoded LMP1 downregulates TCL1 oncogene through miR-29b. Oncogene. 2010, 29: 1316-1328. 10.1038/onc.2009.439CrossRefPubMed
32.
Yin Q, McBride J, Fewell C: MicroRNA-155 is an Epstein-Barr virus-induced gene that modulates Epstein-Barr virus-regulated gene expression pathways. J Virol. 2008, 82: 5295-5306. 10.1128/JVI.02380-07PubMedCentralCrossRefPubMed
33.
Motsch N, Pfuhl T, Mrazek J, Barth S, Grässer FA: Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) induces the expression of the cellular microRNA miR-146a. RNA Biol. 2007, 4: 131-137. 10.4161/rna.4.3.5206CrossRefPubMed
34.
35.
Cameron JE, Yin Q, Fewell C: Epstein-Barr virus latent membrane protein 1 induces cellular MicroRNA miR-146a, a modulator of lymphocyte signaling pathways. J Virol. 2008, 82: 1946-1958. 10.1128/JVI.02136-07PubMedCentralCrossRefPubMed
36.
Rogatsch H, Bonatti H, Menet A, Larcher C, Feichtinger H, Dirnhofer S: Epstein-Barr virus-associated multicentric leiomyosarcoma in an adult patient after heart transplantation: case report and review of the literature. Am J Surg Pathol. 2000, 24: 614-621. 10.1097/00000478-200004000-00018CrossRefPubMed
37.
Rougemont AL, Alfieri C, Fabre M: Atypical Epstein-Barr virus (EBV) latent protein expression in EBV-associated smooth muscle tumours occurring in paediatric transplant recipients. Histopathology. 2008, 53: 363-367. 10.1111/j.1365-2559.2008.03086.xCrossRefPubMed
38.
Cheng Y, Liu X, Yang J: MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res. 2009, 105: 158-166. 10.1161/CIRCRESAHA.109.197517PubMedCentralCrossRefPubMed
39.
Cordes KR, Sheehy NT, White MP: miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature. 2009, 460: 705-710.PubMedCentralPubMed
40.
Bockmeyer CL, Maegel L, Janciauskiene S: Plexiform vasculopathy of severe pulmonary arterial hypertension and microRNA expression. J Heart Lung Transplant. 2012, 31: 764-772. 10.1016/j.healun.2012.03.010CrossRefPubMed
41.
Chaves NJ, Kotsimbos TC, Warren MA: Cranial leiomyosarcoma in an Epstein-Barr virus (EBV)-mismatched lung transplant recipient. J Heart Lung Transplant. 2007, 26: 753-755. 10.1016/j.healun.2007.05.007CrossRefPubMed
42.
Jiang X, Huang H, Li Z: Blockade of miR-150 Maturation by MLL-Fusion/MYC/LIN-28 Is Required for MLL-Associated Leukemia. Cancer Cell. 2012, 22: 524-535. 10.1016/j.ccr.2012.08.028PubMedCentralCrossRefPubMed
43.
Huang S, Guo W, Tang Y, Ren D, Zou X, Peng X: miR-143 and miR-145 inhibit stem cell characteristics of PC-3 prostate cancer cells. Oncol Rep. 2012, 28: 1831-1837.PubMed
44.
45.
Jazbutyte V, Thum T: MicroRNA-21: from cancer to cardiovascular disease. Curr Drug Targets. 2010, 11: 926-935. 10.2174/138945010791591403CrossRefPubMed
Metadata
Title
MicroRNA expression in Epstein-Barr virus-associated post-transplant smooth muscle tumours is related to leiomyomatous phenotype
Authors
Danny Jonigk
Nicole Izykowski
Lavinia Maegel
Eileen Schormann
Britta Maecker-Kolhoff
Florian Laenger
Hans Kreipe
Kais Hussein
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Clinical Sarcoma Research / Issue 1/2013
Electronic ISSN: 2045-3329
DOI
https://doi.org/10.1186/2045-3329-3-9

Other articles of this Issue 1/2013

Clinical Sarcoma Research 1/2013 Go to the issue

Research

Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options

Research

Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients

Research

Endometrial stromal tumors: immunohistochemical and molecular analysis of potential targets of tyrosine kinase inhibitors

Review

Mesenchymal stem cell transformation and sarcoma genesis

Case Report

Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib

Research

The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits